Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Gap Up – Time to Buy?

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) gapped up prior to trading on Wednesday . The stock had previously closed at $24.21, but opened at $26.10. Damora Therapeutics, Inc. Common Stock shares last traded at $26.30, with a volume of 5,209 shares trading hands.

Analyst Upgrades and Downgrades

DMRA has been the subject of a number of analyst reports. TD Cowen assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, June 8th. They set a “buy” rating for the company. HC Wainwright began coverage on Damora Therapeutics, Inc. Common Stock in a research note on Thursday, June 11th. They issued a “buy” rating and a $45.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, June 18th. Royal Bank Of Canada initiated coverage on Damora Therapeutics, Inc. Common Stock in a research report on Friday, April 24th. They set an “outperform” rating and a $40.00 target price for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $35.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research note on Friday, June 12th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $42.43.

Damora Therapeutics, Inc. Common Stock Trading Up 5.0%

The firm’s fifty day moving average price is $23.72 and its 200-day moving average price is $25.47. The company has a market cap of $1.68 billion, a price-to-earnings ratio of -4.90 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.23). As a group, research analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -1.92 EPS for the current year.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

A number of large investors have recently bought and sold shares of DMRA. Janus Henderson Group PLC bought a new position in Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at approximately $40,000. Virtu Financial LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the third quarter worth $49,000. Two Sigma Investments LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the third quarter worth $76,000. Connective Capital Management LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the third quarter worth $100,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $266,000. 14.20% of the stock is owned by institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical?stage biotechnology company developing small?molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin?3, an extracellular carbohydrate?binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase?like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin?3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin?3 inhibitor being evaluated for systemic fibrotic disorders.